Request a Rep
QUAZAR® AML-001 was designed to evaluate ONUREG® vs placebo as continued treatment for adult patients in first CR/CRi1
Select baseline demographics and disease-related characteristics in the QUAZAR® AML-001 trial1
Kaplan-Meier curve for OS: ITT population in QUAZAR® AML-0011
QUAZAR® AML-001 survival estimates
OS select subgroup analysis
Kaplan-Meier curve for OS: patients with an NPM1 mutation in QUAZAR® AML-001*
The NPM1 mutation, which is prognostically favorable, occurs in ~30% of patients with AML (based on an analysis of 1540 AML patients from 3 prospective multicenter trials).8
QUAZAR® AML-001 retrospective, post hoc subgroup analysis4
28% (66/236) of patients who received ONUREG® and 30% (71/233) of patients who received placebo had an NPM1 mutation at diagnosis.6
Analysis limitations